Finance

Lists
Q3 2026 earnings • released • Revenue miss -7.97%
See results
INVA:NASDAQ
Innoviva Inc
$19.24
-9.50%
(-2.02) 1D
$19.26
+0.10% (+0.020)
Pre-market
Closed: Nov 5, 4:00:01 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for INVA...
Open
$20.59
High
$20.91
Low
$19.19
Mkt. cap
1.39B
Avg. vol.
719.28K
Volume
595.00
P/E ratio
4.64
52-wk high
$25.14
52-wk low
$18.85
EPS
$4.15
Beta
0.38
Shares outstanding
72.24M
No. of employees
159
Open
$20.59
High
$20.91
Low
$19.19
Mkt. cap
1.39B
Avg. vol.
719.28K
Volume
595.00
P/E ratio
4.64
52-wk high
$25.14
52-wk low
$18.85
EPS
$4.15
Beta
0.38
Shares outstanding
72.24M
No. of employees
159
News stories
From web sources and news partners
About Innoviva Inc
CEO-
Employees159
Founded1996
HeadquartersSouth San Francisco, California, United States
SectorHealth Care
IndustryPharmaceutical industry
Websiteinva.com
Analyst ratings
Based on 3 analysts giving stock ratings to INVA in the past 3 months
Strong buy
Buy
3
Hold
0
Sell
0
12-month forecast
Based on 3 Wall Street analysts offering 12 month price targets for INVA in the last 3 months.
Highest
Current $19.24
$46.00 (+139.09%)
Average
$38.00 (+97.51%)
Lowest
$34.00 (+76.72%)
Analyst
Recommendation
Action
Price target
Projected
Date
Les Sulewski
Oppenheimer
Buy
Reiterated
$34.00
+76.7%
11/05/2026
Unknown Analyst
Oppenheimer
Buy
Initiated
$35.00
+81.9%
09/23/2026
Steven Seedhouse
Cantor Fitzgerald
Buy
Maintained
$34.00
+76.7%
08/20/2026
Ram Selvaraju
H.C. Wainwright
Buy
Reiterated
$46.00
+139.1%
08/10/2026
Julian Harrison
BTIG
Buy
Maintained
$42.00
+118.3%
08/05/2026
Asad Haider
Goldman Sachs
Sell
Maintained
$18.00
-6.4%
05/06/2026
Trevor Allred
Oppenheimer
Buy
Downgraded
$35.00
+81.9%
02/26/2026
Last report
Nov 4, 2026
Fiscal period
Q3 2026
- / $0.46
Revenue / Est. (USD)
106.12M / 115.31M
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
114.61M
97.99M
119.59M
106.12M
Cost of goods sold
36.18M
14.46M
21.45M
15.04M
Cost of revenue
36.18M
14.46M
21.45M
15.04M
Research and development expenses
-
5.24M
5.19M
5.21M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
32.08M
32.44M
34.57M
37.02M
Operating expense
38.71M
44.23M
46.39M
48.93M
Total operating expenses
74.89M
58.69M
67.84M
63.97M
Operating income
39.72M
39.30M
51.76M
42.15M
Other non operating income
-612.00K
-366.00K
-15.00K
-118.00K
EBT including unusual items
195.04M
234.56M
-108.02M
-97.61M
EBT excluding unusual items
41.95M
44.49M
53.87M
41.88M
Income tax expense
30.88M
47.97M
-24.60M
-23.72M
Effective tax rate
15.83%
20.45%
22.77%
24.30%
Other operating expenses
-
-
-
-
Net income
164.15M
186.60M
-83.42M
-73.89M
Net profit margin
143.22%
190.41%
-69.75%
-69.63%
Earnings per share
0.47
0.47
0.56
-
Interest and investment income
6.15M
10.99M
7.60M
5.32M
Interest expense
-3.31M
-5.44M
-5.47M
-5.47M
Net interest expenses
2.84M
5.55M
2.13M
-156.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
46.39M
45.89M
58.45M
48.75M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps